ReNeuron has announced the long-awaited dosing of the first patient in its placebo-controlled US Phase IIb (PISCES III) study in patients six to 12 months after ischemic stroke. The news has been well-received as it is rare for a small UK biotech to start dosing US patients with a novel stem cell-derived product.
24 Jan 2019
ReNeuron Group - Formative event
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Formative event
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
24 Jan 2019 -
Author:
Dr Andy Smith -
Pages:
2
ReNeuron has announced the long-awaited dosing of the first patient in its placebo-controlled US Phase IIb (PISCES III) study in patients six to 12 months after ischemic stroke. The news has been well-received as it is rare for a small UK biotech to start dosing US patients with a novel stem cell-derived product.